Health TrialsbyHealthPanel

Study of Cognitive-Linguistic Profiles: The Role of Executive Control in Aphasia

ConditionStroke
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity Hospital, Toulouse

About this trial

In France, stroke affects 150,000 people annually and is the leading cause of acquired disability in adults; 10-12% of patients exhibit mild post-stroke aphasia, a condition defined by language difficulties.

Few studies describe mild post-stroke aphasia, and none characterize the impairment of linguistic executive control in this population; consequently, its prevalence remains unknown. To date, the role of linguistic executive control in mild aphasia remains an open question.

The aim of this project is to investigate linguistic executive control impairment in stroke survivors with mild aphasia, provide an initial estimate of its prevalence, and demonstrate its interactions with other linguistic and communicative aspects, as well as with executive and attentional functions.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient who has experienced a first ischemic stroke resulting in clinical symptoms within the last 3 months and is receiving care in the Physical Medicine and Rehabilitation department.

Score ≤ 31 on the conversational speech observation scale of the MEC test (Montreal Protocol for the Evaluation of Communication).

Patients with a BDAE score ≥ 3 (Boston Diagnostic Aphasia Examination - French version, Mazaux J.-M. [1990]); this score is the gold standard in aphasiology.

Native French-speaking patient capable of understanding oral or written instructions.

Disqualifiers

Patients exhibiting behavior or a clinical condition incompatible with test administration, as assessed by the clinician.

Known major visual, auditory, or motor impairments incompatible with test performance.

Known neurodegenerative and/or neurodevelopmental disorders.

Known social cognition disorders (e.g., ASD).

Trial design

Design model

Single group

Treatments tested in this trial

  • Neuropsychological tests

    Diagnostic test

    Patients undergo neuropsychological tests, the order of which will be randomized.

  • Speech-language assessments

    Diagnostic test

    Patients will undergo speech-language assessments, with the order of the tests randomized.

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: Patients whose neuropsychological and speech-language pathology tests will be randomizedExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

measure the proportion of patients with mild post-stroke aphasia exhibiting deficits in linguistic executive control within three months of a first stroke

CATEX score result (deficit score if below the mean value minus 1.65 times the standard deviation)

Time frame
7 days after the inclusion

Secondary outcomes

1

Study of the correlation between executive control of language (CATEX score) and the score of the test evaluating access to the lexical stock

Time frame
7 days after the inclusion
2

Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating access to the semantic system

Time frame
7 days after the inclusion
3

Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating non-verbal executive control

Time frame
7 days after the inclusion
4

Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating gnosies

Time frame
7 days after the inclusion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Toulouse

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: